Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death approximately every 9 minutes with over 59,000 deaths and 665,000 ...

In total, 5% of dogs and 13% of cats tested positive for COVID-19 on polymerase chain reaction, and 25% and 36%, respectively ...

New research emphasizes the need for ongoing COVID-19 protection for people with weakened immune systems, with scalable tests ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

The antibody targets a stable part of the bird flu virus, ensuring that the immune protection can resist new variants and offer long-term protection against the globally spreading airborne infection.

University of Idaho researchers found that the COVID-19 vaccine does not have any adverse effects on a mother’s breast milk.

The virus often mutates by simply deleting small pieces of its genetic code. The mutations "disguise" the virus from ...

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of ...

“Although individual vaccines have been developed and approved for use in humans against SARS-CoV-2 and influenza viruses, ...

Invivyd announced that a manuscript preprint conveying data from the CANOPY Phase 3 clinical trial of pemivibart for the pre-exposure prophylaxis of COVID-19, including long-term protection shown ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.